ArticleJournal of translational medicine2025
Roseburia intestinalis-derived inosine improves intestinal motility by activating TGF-β1/p-Smad3/Transgelin signaling axis.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundFunctional constipation (FC) is a prevalent gastrointestinal disorder marked by impaired intestinal motility, affecting millions worldwide and significantly diminishing quality of life. Current therapeutic strategies provide only transient symptom relief and fail to restore colonic motor function. This study aims to explore the causal role of gut microbiota in FC, focusing on the mechanisms by which Roseburia intestinalis (RI) and its metabolite inosine improve intestinal motility.
methodsTo identify protective gut taxa, we first performed bidirectional Mendelian randomization (MR) integrated with 16S rRNA sequencing on fecal samples from 30 FC patients and 30 healthy controls. Loperamide-induced constipation mouse models evaluated RI gavage effects on motility indicators, including fecal output (frequency and water content), gastrointestinal transit time, intestinal propulsion rate, colonic bead expulsion time, and ex vivo organ bath contractions. To elucidate the underlying mechanism, we conducted RNA sequencing on colonic tissues. Furthermore, comparative metabolomics was employed to identify the key bacterial metabolites responsible for RI's effects. Finally, the proposed mechanism of action for both RI and its key metabolite was validated through a combination of histology, immunohistochemistry, immunofluorescence, quantitative PCR, and Western blot analyses.
resultsMR and sequencing identified RI as a protective factor (OR = 0.8675, P < 0.05), with reduced abundance in FC patients negatively correlating with symptom severity and quality-of-life scores. In constipation mouse models, RI gavage promoted intestinal motility, enhanced fecal water content and gastrointestinal transit, and ameliorated mucosal injury while improving mucus secretion. RNA sequencing revealed upregulation of Tagln (transgelin) and enrichment of the TGF-β pathway after RI intervention. Metabolomics analysis pinpointed inosine as a key RI-derived small-molecule metabolite, enriched in RI supernatant and depleted in FC patient feces. Inosine gavage improved motility and histology, increased TGF-β1, p-Smad3, and transgelin, and these effects were abolished by the TGF-β receptor inhibitor SB431542.
conclusionsThese findings established that RI and its metabolite inosine promote intestinal motility via TGF-β1/p-Smad3 signaling and identified transgelin as the terminal effector of this cascade, offering mechanistic insight into microbiota-host interactions and pointing to therapeutic targets for gastrointestinal motility disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.